DE102011057021A1 - Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten - Google Patents

Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten Download PDF

Info

Publication number
DE102011057021A1
DE102011057021A1 DE102011057021A DE102011057021A DE102011057021A1 DE 102011057021 A1 DE102011057021 A1 DE 102011057021A1 DE 102011057021 A DE102011057021 A DE 102011057021A DE 102011057021 A DE102011057021 A DE 102011057021A DE 102011057021 A1 DE102011057021 A1 DE 102011057021A1
Authority
DE
Germany
Prior art keywords
beta
aggregates
probes
substrate
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102011057021A
Other languages
German (de)
English (en)
Inventor
Dieter Willbold
Susanne Aileen Funke
Eva Birkmann
Oliver Bannach
Lei Wang-Dietrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Priority to DE102011057021A priority Critical patent/DE102011057021A1/de
Priority to DK12818996.6T priority patent/DK2794655T3/da
Priority to CA2858125A priority patent/CA2858125A1/en
Priority to CN201280064163.5A priority patent/CN104080807A/zh
Priority to RU2014130136A priority patent/RU2642314C2/ru
Priority to US14/366,952 priority patent/US20150024512A1/en
Priority to ES12818996T priority patent/ES2922201T3/es
Priority to BR112014015392A priority patent/BR112014015392A2/pt
Priority to EP12818996.6A priority patent/EP2794655B1/de
Priority to JP2014548051A priority patent/JP2015502551A/ja
Priority to PCT/EP2012/076552 priority patent/WO2013092952A2/de
Publication of DE102011057021A1 publication Critical patent/DE102011057021A1/de
Priority to IL232870A priority patent/IL232870B/en
Priority to JP2018189249A priority patent/JP6625709B2/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE102011057021A 2011-12-23 2011-12-23 Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten Ceased DE102011057021A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE102011057021A DE102011057021A1 (de) 2011-12-23 2011-12-23 Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
BR112014015392A BR112014015392A2 (pt) 2011-12-23 2012-12-21 método e kit para quantificar e/ou caracterizar seletivamente agregados de a-beta; método para a determinação da eficácia das substâncias ativas e/ou terapias para o tratamento de ad; método para decidir sobre a aceitação de um indivíduo em estudo ou teste clínico; sondas; e uso de sondas específicas agregados de a-beta ou sondas específicas a oligômeros de a-beta
EP12818996.6A EP2794655B1 (de) 2011-12-23 2012-12-21 Verfahren zur selektiven quantifizierung von a-beta-aggregaten
CN201280064163.5A CN104080807A (zh) 2011-12-23 2012-12-21 选择性量化A-β聚集体的方法
RU2014130136A RU2642314C2 (ru) 2011-12-23 2012-12-21 Способы избирательной количественной оценки агрегатов а-бета
US14/366,952 US20150024512A1 (en) 2011-12-23 2012-12-21 Method for selectively quantifying a-beta aggregates
ES12818996T ES2922201T3 (es) 2011-12-23 2012-12-21 Procedimiento de cuantificación selectiva de agregados A-beta
DK12818996.6T DK2794655T3 (da) 2011-12-23 2012-12-21 Fremgangsmåde til selektiv mængdebestemmelse af a-beta-aggregater
CA2858125A CA2858125A1 (en) 2011-12-23 2012-12-21 Methods for selectively quantifying a-beta aggregates
JP2014548051A JP2015502551A (ja) 2011-12-23 2012-12-21 Ａβ凝集体の選択的定量化方法
PCT/EP2012/076552 WO2013092952A2 (de) 2011-12-23 2012-12-21 Verfahren zur selektiven quantifizierung von a-beta-aggregaten
IL232870A IL232870B (en) 2011-12-23 2014-05-29 Methods for selective quantification of cell aggregates
JP2018189249A JP6625709B2 (ja) 2011-12-23 2018-10-04 Ａβ凝集体の選択的定量化方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011057021A DE102011057021A1 (de) 2011-12-23 2011-12-23 Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten

Publications (1)

Publication Number Publication Date
DE102011057021A1 true DE102011057021A1 (de) 2013-06-27

Family

ID=47624003

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102011057021A Ceased DE102011057021A1 (de) 2011-12-23 2011-12-23 Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten

Country Status (12)

Country Link
US (1) US20150024512A1 (https=)
EP (1) EP2794655B1 (https=)
JP (2) JP2015502551A (https=)
CN (1) CN104080807A (https=)
BR (1) BR112014015392A2 (https=)
CA (1) CA2858125A1 (https=)
DE (1) DE102011057021A1 (https=)
DK (1) DK2794655T3 (https=)
ES (1) ES2922201T3 (https=)
IL (1) IL232870B (https=)
RU (1) RU2642314C2 (https=)
WO (1) WO2013092952A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207049A2 (de) 2013-06-26 2014-12-31 Forschungszentrum Jülich GmbH Verfahren zur ermittlung von indikatoren zur bestimmung von krankheiten
WO2018228622A1 (de) * 2017-06-13 2018-12-20 Forschungszentrum Jülich GmbH Verfahren zum nachweis von aggregaten biotherapeutischer substanzen in einer probe
WO2021239700A2 (de) 2020-05-28 2021-12-02 Forschungszentrum Jülich GmbH Bestimmung krankheitsspezifischer protein-aggregate in stuhlproben
WO2021259406A1 (de) * 2020-06-25 2021-12-30 Forschungszentrum Jülich GmbH Verfahren, verwendung des verfahrens sowie kit zum nachweis von bioindikatoren in einer probe

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6925265B2 (ja) * 2014-09-16 2021-08-25 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ 光ファイバーアレイ走査技術による親和性試薬および触媒の発見 本発明は、Ｓｐａｃｅ ａｎｄ Ｎａｖａｌ Ｗａｒｆａｒｅ Ｓｙｓｔｅｍｓ Ｃｏｍｍａｎｄ Ｓｙｓｔｅｍｓ Ｃｅｎｔｅｒ Ｐａｃｉｆｉｃから授与された契約番号Ｎ６６００１−１４−Ｃ−４０５９に基づく国庫補助でなされたものである。政府は、本発明に関してある権利を有する。
DE102015003404B4 (de) * 2015-03-18 2021-10-07 Forschungszentrum Jülich GmbH Verfahren zur Herstellung eines Standards für den Nachweis von Proteinaggregaten einer Proteinfehlfaltungserkrankung sowie Standard und dessen Verwendung
EP3415912B1 (en) * 2016-02-08 2023-03-29 Sysmex Corporation Analyte detection method and reagent kit for detecting analyte
JP6886854B2 (ja) 2017-04-13 2021-06-16 シスメックス株式会社 被検物質の情報取得方法
DE102017005543A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Extrazellulären Vesikeln in einer Probe
DE102017010842A1 (de) * 2017-11-23 2019-05-23 Forschungszentrum Jülich GmbH Verfahren zur Quantifizierung von Proteinaggregaten einer Proteinfehlfaltungserkrankung in einer Probe
WO2019126395A1 (en) * 2017-12-19 2019-06-27 Chase Therapeutics Corporation Methods for developing pharmaceuticals for treating neurodegenerative conditions
CN111518206B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN116879540B (zh) * 2023-07-13 2024-04-05 香港中文大学（深圳） 一种神经元蛋白聚集体特异性检测试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
DE69533623T2 (de) * 1994-11-14 2006-03-02 Elan Pharmaceuticals, Inc., San Francisco Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau
WO2008070229A2 (en) * 2006-08-28 2008-06-12 Case Western Reserve University Detection of pathogenic aggregates of protein in a sample by homologous elisa

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE462454B (sv) * 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US7258990B2 (en) * 2004-08-19 2007-08-21 Biocept, Inc. Alleviation of non-specific binding in microarray assays
HRP20140240T4 (hr) * 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
KR20080097188A (ko) * 2006-02-24 2008-11-04 키에시 파르마슈티시 엣스. 피. 에이. 항아밀로이드 면역성성분, 그 제조방법 및 용도
CN101965365A (zh) * 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
CN102089659A (zh) * 2008-05-08 2011-06-08 武田药品工业株式会社 Aβ寡聚物的测定方法
JP5720248B2 (ja) * 2008-12-24 2015-05-20 コニカミノルタ株式会社 表面プラズモンおよび蛍光共鳴エネルギー転移を利用した免疫アッセイ
US8512677B2 (en) * 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
JP2013518927A (ja) * 2010-02-09 2013-05-23 ブリストル−マイヤーズ スクイブ カンパニー 免疫アッセイ標準物質およびアッセイ内の校正標準物質を用いる臨床バイオマーカーの測定

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69533623T2 (de) * 1994-11-14 2006-03-02 Elan Pharmaceuticals, Inc., San Francisco Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2008070229A2 (en) * 2006-08-28 2008-06-12 Case Western Reserve University Detection of pathogenic aggregates of protein in a sample by homologous elisa

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chafekar, S. M. [u.a.]: Branched KLVFF Tetramers Strongly Potentiate Inhibition of beta-Amyloid Aggregation. In: ChemBioChem (2007), Vol. 8, Seiten 1857 - 1864 *
Chafekar, S. M. [u.a.]: Branched KLVFF Tetramers Strongly Potentiate Inhibition of β-Amyloid Aggregation. In: ChemBioChem (2007), Vol. 8, Seiten 1857 - 1864
Janissen et al. (Colloids Surf B Biointerfaces, 2009, 71(2), 200-207)
Needleman, S.B. und Wunsch, C.D. (J. Mol. Biol. 48: 443-453)
Smith, T.F. und Waterman, M.S (Adv. Appl. Math. 2: 482-489 (1981))

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207049A2 (de) 2013-06-26 2014-12-31 Forschungszentrum Jülich GmbH Verfahren zur ermittlung von indikatoren zur bestimmung von krankheiten
DE102013106713A1 (de) * 2013-06-26 2014-12-31 Forschungszentrum Jülich GmbH Verfahren zur Ermittlung von Indikatoren zur Bestimmung von Krankheiten
US11175288B2 (en) 2013-06-26 2021-11-16 Forschungszentrum Juelich Gmbh Method for detecting indicators for determining diseases
EP4180815A2 (de) 2013-06-26 2023-05-17 Forschungszentrum Jülich GmbH Immunologischer festphasen-test mit ortsaufgelöstem signal (sfida) zur quantifizierung von mindestens 2 proteinaggregaten
WO2018228622A1 (de) * 2017-06-13 2018-12-20 Forschungszentrum Jülich GmbH Verfahren zum nachweis von aggregaten biotherapeutischer substanzen in einer probe
WO2021239700A2 (de) 2020-05-28 2021-12-02 Forschungszentrum Jülich GmbH Bestimmung krankheitsspezifischer protein-aggregate in stuhlproben
DE102020114278A1 (de) 2020-05-28 2021-12-02 Forschungszentrum Jülich GmbH Bestimmung krankheitsspezifischer Protein-Aggregate in Stuhlproben
WO2021259406A1 (de) * 2020-06-25 2021-12-30 Forschungszentrum Jülich GmbH Verfahren, verwendung des verfahrens sowie kit zum nachweis von bioindikatoren in einer probe

Also Published As

Publication number Publication date
WO2013092952A3 (de) 2013-08-29
EP2794655A2 (de) 2014-10-29
EP2794655B1 (de) 2022-04-13
IL232870B (en) 2020-06-30
RU2642314C2 (ru) 2018-01-24
CN104080807A (zh) 2014-10-01
CA2858125A1 (en) 2013-06-27
WO2013092952A2 (de) 2013-06-27
BR112014015392A2 (pt) 2019-09-24
US20150024512A1 (en) 2015-01-22
RU2014130136A (ru) 2016-02-10
JP2019015738A (ja) 2019-01-31
JP2015502551A (ja) 2015-01-22
JP6625709B2 (ja) 2019-12-25
ES2922201T3 (es) 2022-09-09
IL232870A0 (en) 2014-07-31
DK2794655T3 (da) 2022-07-18

Similar Documents

Publication Publication Date Title
DE102011057021A1 (de) Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
EP3014279B1 (de) Verfahren zur bestimmung von proteinaggregaten unter verwendung von oberflächen-fida
DE602004001533T2 (de) Immunoassay von kardialem Troponin I
WO2004090546A1 (de) Bestimmung eines midregionalen proadrenomedullin-teilpeptids in biologischen flüssigkeiten zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung
WO2018228625A1 (de) Verfahren zum nachweis von extrazellulären vesikeln in einer probe
EP3470847A2 (de) Standard zur quantifizierung von pathogenen aggregaten aus körpereigenen proteinen
JP2015502551A5 (https=)
EP1425584A2 (de) Verbesserte massenspektrometrische analyse unter verwendung von nanopartikeln
EP3260865A2 (de) Verfahren zur behandlung von blut, blutprodukten und organen
WO2021239700A2 (de) Bestimmung krankheitsspezifischer protein-aggregate in stuhlproben
DE102018209516A1 (de) Verfahren zur Bestimmung von Analyten mittels kompetitiver Bindungsreaktion
EP1493034A2 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
WO2018228622A1 (de) Verfahren zum nachweis von aggregaten biotherapeutischer substanzen in einer probe
EP3714274A1 (de) Verfahren zur quantifizierung von proteinaggregaten einer proteinfehlfaltungserkrankung in einer probe
EP1902317B1 (de) Verfahren zur selektiven bestimmung pathologischer proteinablagerungen
WO2003054548A1 (de) Verfahren zur quantitativ analytischen bestimmung von aggregaten
DE102020003794A1 (de) Verfahren, Verwendung des Verfahrens sowle Kit zum Nachweis von Bioindikatoren in einer Probe
EP1600774A1 (de) Verfahren zur Identifizierung von Substanzen zur Beeinflussung der Aggregationen von Proteinen

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R082 Change of representative

Representative=s name: FITZNER PARTGMBB RECHTSANWALT UND PATENTANWAEL, DE

Representative=s name: DRES. FITZNER UND PARTNER RECHTS- UND PATENTAN, DE

R016 Response to examination communication
R082 Change of representative

Representative=s name: MEISSNER BOLTE PATENTANWAELTE RECHTSANWAELTE P, DE

R016 Response to examination communication
R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final